Authors: Shafic Makumbi, Abbas Lugemwa, Deborah Ford, Anna Turkova, Francis Bajunirwe, Victor Musiime, Diana Gibb, Imelda K Tamwesigire Presented at : International Workshop on HIV & Pediatrics Read

Search
results
Search
ResultsVoluntary Consent to Research on HIV-infected Children in the CHAPAS-4 and ODYSSEY HIV Clinical Trials. Abstract
Authors: Shafic Makumbi, Abbas Lugemwa, Deborah Ford, Anna Turkova, Francis Bajunirwe, Victor Musiime, Diana Gibb, Imelda K Tamwesigire Abstract Introduction: Voluntariness among parents consenting for research in their children is hard to assess and there have been...
Double dose of dolutegravir to treat HIV in children also being treated for tuberculosis
Results from a substudy of the ODYSSEY trial show that children being treated for tuberculosis (TB) and HIV at the same time can safely have the anti-HIV medicine dolutegravir twice a day. These results were published yesterday in The Lancet HIV journal. Around 50,000...
Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial
Authors: H Waalewijn, M.K Chan, P.D.J Bollen, H.A Mujuru, S Makumbi, A.R Kekitiinwa, E Kaudha, T Sarfati, G Musoro, A Nanduudu, A Lugemwa, P Amuge, C.L Moore, P Rojo, C Giaquinto, A Colbers, D.M Gibb, D Ford, A Turkova, D.M Burger Published in: The Lancet ...
Borrowing information across patient subgroups in clinical trials, with application to a paediatric trial
Authors: R.M. Turner, A Turkova, C.L. Moore, A Bamford, M Archary, L.N. Barlow-Mosha, M.F. Cotton, T.R. Cressey, E Kaudha, A Lugemwa, H Lyall, H.A. Mujuru, V Mulenga, V Musiime, P Rojo, G Tudor-Williams, S.B. Welch, D.M. Gibb, D Ford, I.R. White & and the ODYSSEY...
Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children
Authors: A Turkova, E White, HA. Mujuru, AR. Kekitiinwa, CM. Kityo, A Violari, A Lugemwa, TR. Cressey, P Musoke, E Variava, MF. Cotton, M Archary, et al for the ODYSSEY Trial Team Presented at: The New England Journal of Medicine Read
Easy-to-take medicine better at suppressing HIV in children
A once-a-day antiretroviral medicine that is low-cost and easy for children to take is also more effective at suppressing HIV than standard treatments, according to a global trial led by researchers at UCL.
ODYSSEY trial wins 2021 Hector Award
It was announced at the 8th European AIDS Conference that the laureates of the Hector Research Award in HIV 2021 in clinical and/or epidemiological science was received Angela Colbers and David Burger on behalf of the ODYSSEY trial team! The winning paper Simplified...
Dolutegravir-Based ART is Superior to Standard of Care in Young Children Living With HIV (combined results of the main trial and the ‘under 14kg’ cohort)
Authors: Anna Turkova on behalf of the ODYSSEY trial team Presented at: CHIVA 2021 (Oral presentation) Download
Dolutegravir-Based ART is Superior to Standard of Care in Young Children Living With HIV
Authors: Pauline Amuge on behalf of the ODYSSEY trial team Published in: International workshop on HIV pediatrics 2021 (Oral presentation) Download